Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients.

Tingting LiQingya CuiSining LiuZheng LiWei CuiMengyun LiYunju MaXuanqi CaoXiaming ZhuLiqing KangLei YuDepei WuXiaowen Tang

Published in: Leukemia research (2024)

Our study recommends decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance strategy to improve the survival outcomes of patients with r/r B-ALL.

Keyphrases

acute myeloid leukemia
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
acute lymphoblastic leukemia
peritoneal dialysis
prognostic factors
multiple myeloma
replacement therapy
patient reported
smoking cessation